Biology subjects

Vingtdeux, V.

Publications and source records attributed to Vingtdeux, V..

3 recordsLinked to original sources

bioRxiv2018

AMP-activated protein kinase is essential for the maintenance of energy levels during synaptic activation

While accounting for 2% of the total body mass, the brain is the organ that consumes the most energy. Although it is widely acknowledged that neuronal energy metabolism is tightly regulated, the mechanism how neurons meet their energy demand to sustain synaptic transmission remains poorly studied. Here we provide substantial evidence that the AMP-activated protein kinase (AMPK) plays a leading role in this process. Our results show that following synaptic activation, AMPK activation is required to sustain neuronal energy levels particularly through mitochondrial respiration. Further, our studies revealed that this metabolic plasticity regulated by AMPK is required for the expression of immediate early genes, synaptic plasticity and memory formation. These findings are important in the context of neurodegenerative disorders, as AMPK deregulation as it is observed in Alzheimers disease, impairs the metabolic response to synaptic activation. Altogether, our data provides the proof of concept that AMPK is an essential player in the regulation of neuroenergetic metabolism plasticity induced in response to synaptic activation.

neuroscience↗

bioRxiv2018

Contribution of the endosomal-lysosomal and proteasomal systems in Amyloid-β Precursor Protein derived fragments processing

A{beta} peptides, the major components of amyloid deposits of Alzheimers disease, are released following sequential cleavages by secretases of its precursor named the amyloid precursor protein (APP). In addition to secretases, degradation pathways, in particular the endosomal/lysosomal and proteasomal systems have also been reported to contribute to APP processing. However, the respective role of each of these pathways towards APP metabolism remains to be established. To address this, we used HEK 293 cells and primary neurons expressing full-length APPWT or the {beta}-secretase-derived C99 fragments ({beta}-CTFs) in which degradation pathways were selectively blocked using pharmacological drugs. APP metabolites, including carboxy-terminal fragments (CTFs), soluble APP (sAPP) and A{beta} peptides were studied. In this report, we show that APP-CTFs produced from endogenous or overexpressed full-length APP are mainly processed by {gamma}-secretase and the endosomal/lysosomal pathway, while in sharp contrast, overexpressed C99 alone is mainly degraded by the proteasome and to a lesser extent by {gamma}-secretase.

neuroscience↗

bioRxiv2016

A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides

Strategies aimed at reducing cerebral accumulation of the amyloid-{beta} (A{beta}) peptides have therapeutic potential in Alzheimers disease (AD). A{beta} immunization has proven to be effective at promoting A{beta} clearance in animal models but adverse effects have hampered its clinical evaluation. The first anti-A{beta} immunization clinical trial, which assessed a full-length A{beta}1-42 vaccine, increased the risk of encephalitis most likely because of autoimmune pro-inflammatory T helper 1 (Th1) response against all forms of A{beta}. Immunization against less abundant but potentially more pathologically relevant A{beta} products, such as N-terminally-truncated pyroglutamate-3 A{beta} (A{beta}pE3), could provide efficacy and improve tolerability in A{beta} immunotherapy. Here, we describe a selective vaccine against A{beta}pE3 using the diphtheria toxin mutant CRM197 as carrier protein for epitope presentation. CRM197 is currently used in licensed vaccines and has demonstrated excellent immunogenicity and safety in humans. In mice, our A{beta}pE3:CRM197 vaccine triggered the production of specific anti-A{beta}pE3 antibodies that did not cross-react with A{beta}1-42, non-cyclized A{beta}E3, or N-terminally-truncated pyroglutamate-11 A{beta} (A{beta}pE11). A{beta}pE3:CRM197 antiserum strongly labeled A{beta}pE3 in insoluble protein extracts and decorated cortical amyloid plaques in human AD brains. Anti-A{beta}pE3 antibodies were almost exclusively of the IgG1 isotype, suggesting an anti-inflammatory Th2 response bias to the A{beta}pE3:CRM197 vaccine. To the best of our knowledge, this study shows for the first time that CRM197 has potential as a safe and suitable vaccine carrier for active and selective immunization against specific protein sequence modifications or conformations, such as A{beta}pE3.

neuroscience↗